{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:19:31Z","timestamp":1791584371730,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ard.2026.05.021","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:38:41Z","timestamp":1781901521000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2697-9080","authenticated-orcid":false,"given":"Fredrik N","family":"Albach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpida","family":"Phithak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-7832","authenticated-orcid":false,"given":"Robert","family":"Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Minopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engi","family":"Algharably","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Casteleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E","family":"Beenken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Trezzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Sinzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Unterwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Staeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Luise","family":"H\u00fctter-Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Exner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christin","family":"Pecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Kaudewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Sondergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Troldborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns-Martin","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-7820","authenticated-orcid":false,"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-0097","authenticated-orcid":false,"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ard.2026.05.021_bib0001","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"10.1016\/j.ard.2026.05.021_bib0002","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol."},{"issue":"6","key":"10.1016\/j.ard.2026.05.021_bib0003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.ard.2026.05.021_bib0004","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.ard.2026.05.021_bib0005","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ard.2026.05.021_bib0006","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ard.2025.05.007","article-title":"One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn's-like inflammatory bowel disease","volume":"84","author":"Lorenz","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.ard.2026.05.021_bib0007","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ard.2025.01.043","article-title":"Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation","volume":"84","author":"Siegert","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.05.021_bib0008","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ard.2025.09.012","article-title":"Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase Syndrome","volume":"85","author":"Phithak","year":"2026","journal-title":"Ann Rheum Dis."},{"issue":"15","key":"10.1016\/j.ard.2026.05.021_bib0009","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-Cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ard.2026.05.021_bib0010","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-026-04238-4","article-title":"Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases","volume":"32","author":"D\u00fcsing","year":"2026","journal-title":"Nat Med."},{"issue":"5","key":"10.1016\/j.ard.2026.05.021_bib0011","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Target Oncol."},{"issue":"11","key":"10.1016\/j.ard.2026.05.021_bib0012","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41409-025-02695-y","article-title":"Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee","volume":"60","author":"Alexander","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ard.2026.05.021_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ard.2026.05.021_bib0014","unstructured":"Teclistamab: summary of product characteristics. First published: 13\/10\/2022. Last updated: 08\/10\/2025 [cited 05 Jan 2026]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecvayli"},{"issue":"4","key":"10.1016\/j.ard.2026.05.021_bib0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"35","key":"10.1016\/j.ard.2026.05.021_bib0016","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol."},{"issue":"16","key":"10.1016\/j.ard.2026.05.021_bib0017","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.ard.2026.05.021_bib0018","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.ard.2026.05.021_bib0019","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"10.1016\/j.ard.2026.05.021_bib0020","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.05.021_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102615","article-title":"Clinical disease activity and flare in SLE: Current concepts and novel biomarkers","volume":"119","author":"Thanou","year":"2021","journal-title":"J Autoimmun."},{"issue":"5","key":"10.1016\/j.ard.2026.05.021_bib0022","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","article-title":"The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment","volume":"11","author":"Luijten","year":"2012","journal-title":"Autoimmun Rev."},{"issue":"1","key":"10.1016\/j.ard.2026.05.021_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med."},{"issue":"11","key":"10.1016\/j.ard.2026.05.021_bib0024","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.23543","article-title":"An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index","volume":"70","author":"Wallace","year":"2018","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"11","key":"10.1016\/j.ard.2026.05.021_bib0025","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41409-025-02684-1","article-title":"Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation","volume":"60","author":"Del Papa","year":"2025","journal-title":"Bone Marrow Transplant."},{"issue":"9","key":"10.1016\/j.ard.2026.05.021_bib0026","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.ard.2026.05.021_bib0027","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.ard.2026.05.021_bib0028","unstructured":"European Medicines Agency. Tecvayli (teclistamab): EPAR\u2014Public Assessment Report. EMA\/789141\/2022. 2022 Jul 21 [cited 05 Jan 2026]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/tecvayli-epar-public-assessment-report_en.pdf"},{"issue":"4","key":"10.1016\/j.ard.2026.05.021_bib0029","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11523-022-00893-y","article-title":"Translational modeling predicts efficacious therapeutic dosing range of Teclistamab for multiple myeloma","volume":"17","author":"Girgis","year":"2022","journal-title":"Target Oncol."},{"issue":"7","key":"10.1016\/j.ard.2026.05.021_bib0030","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol."},{"key":"10.1016\/j.ard.2026.05.021_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1392831","article-title":"Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis","volume":"15","author":"Han","year":"2024","journal-title":"Front Neurol."},{"key":"10.1016\/j.ard.2026.05.021_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2026.02.002","article-title":"Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series","author":"Scherlinger","year":"2026","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.ard.2026.05.021_bib0033","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med."},{"issue":"1","key":"10.1016\/j.ard.2026.05.021_bib0034","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.ard.2026.05.021_bib0035","first-page":"1291","article-title":"Crohn's disease following Rituximab treatment for follicular lymphoma in a patient with synchronous gastric signet ring cells carcinoma: a case report and literature review","volume":"52","author":"Cavalcanti","year":"2020","journal-title":"Cancer Res Treat."},{"issue":"6","key":"10.1016\/j.ard.2026.05.021_bib0036","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.4049\/jimmunol.1003181","article-title":"Long-lived plasma cells from human small intestine biopsies secrete immunoglobulins for many weeks in vitro","volume":"187","author":"Mesin","year":"2011","journal-title":"J Immunol."},{"issue":"5","key":"10.1016\/j.ard.2026.05.021_bib0037","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/mi.2016.59","article-title":"The human intestinal B-cell response","volume":"9","author":"Spencer","year":"2016","journal-title":"Mucosal Immunol."},{"issue":"6","key":"10.1016\/j.ard.2026.05.021_bib0038","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/mi.2009.106","article-title":"Gut-associated lymphoid tissue contains the molecular machinery to support T-cell-dependent and T-cell-independent class switch recombination","volume":"2","author":"Barone","year":"2009","journal-title":"Mucosal Immunol."},{"issue":"6","key":"10.1016\/j.ard.2026.05.021_bib0039","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/sarh.2001.21904","article-title":"Pulmonary-renal syndrome in systemic sclerosis","volume":"30","author":"Bar","year":"2001","journal-title":"Semin Arthritis Rheum."},{"issue":"Supplement 1","key":"10.1016\/j.ard.2026.05.021_bib0040","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1182\/blood-2025-4066","article-title":"Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: a multicenter study from the U.S. multiple myeloma immunotherapy consortium. The 67th ASH Annual Meeting Abstract","volume":"146","author":"Dae","year":"2025","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.ard.2026.05.021_bib0041","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1093\/rheumatology\/keac065","article-title":"Myocardial fibrosis and arrhythmic burden in systemic sclerosis","volume":"61","author":"Ross","year":"2022","journal-title":"Rheumatology (Oxford)."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:27:41Z","timestamp":1782149261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726003006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"alternative-id":["S0003496726003006"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.05.021","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}